In this study, AR status was assessed at baseline utilizing the PredicineCARE™ cell-free DNA targeted panel.
ctDNA tumor fraction of 0.005 was used to define detectability as per the limit of
detection guidelines from Predicine
September 2024
In collaboration with Bristol Myers Squibb
In this study, PredicineEPIC™ methylation assay was used to monitor treatment response and detect disease progression in advanced NSCLC patients with leptomeningeal metastases treated by Furmonertinib therapies in CSF samples.
September 2024
In collaboration with Henan Cancer Hospital
In this study, cfDNA was extracted and analyzed using PredicineCARE™ for cancer variant profiling and/or PredicineSCORE™ for low-pass whole genome sequencing (LP-WGS).
February 2024
In collaboration with Mayo Clinic
In a single-arm investigator initiated clinical trial for patients with untreated advanced HER2+
gastroesophageal adenocarcinoma, bevacizumab was added to standard of care capecitabine, oxaliplatin, and trastuzumab in 36 patients. The MRD status of mutations identified at time of resistance were tracked on PredicineCARE™ using PredicineCARE™ Ultra. To analyze this data we leveraged the workflow from PredicineBEACON, a personalized MRD assay that tracks up to 50 personalized mutations plus 500 hot spot mutations.
August 2024
In collaboration with Incyte
In this study, PredicineBEACON™ was employed to detect genomic alterations in plasma samples from NSCLC and CRC patients participating in Roche’s clinical trials for the KRAS G12C inhibitor, Divarasib. The assay demonstrated strong correlations between ctDNA dynamics, including tumor fraction (TF), and clinical outcomes. Monitoring TF provided crucial insights into treatment response, further reinforcing the value of PredicineBEACON™ in tracking and predicting therapeutic efficacy.
July 2024
In collaboration with Peter MacCallum Cancer Centre
In the Phase II FIGHT-207 trial, PredicineCARE™ played a crucial role in evaluating pemigatinib in patients with advanced FGFR-altered solid tumors. The trial results were impressive, demonstrating significant responses across multiple tumor types, with a notable 26.5% response rate in patients with FGFR1-3 fusions, including glioblastoma and pancreatic cancers—tumor types not previously known to respond to FGFR inhibitors.
June 2024
In this study, eight commercial assays measuring baseline ctDNA were blinded and included in the
analysis (labeled Cohort A-I). Five assays (62.5%) were tumor-informed (i.e., mutations
identified in the primary tumor tissue that are tracked in the plasma), and three (37.5%)
were tumor-naïve (i.e., mutations were detected de novo from the plasma).
April 2024
In this study HER2-positive MBC patients with no prior therapy in the metastatic setting were retrospectively recruited at two medical centres. cfNDA testing from plasma was conducted using the PredicineCARE™ assay targeting 152 genes.
March 2024
Inthis research study, PredicineCARE™ (Assay G) liquid biopsy next-generation sequencing assay demonstrated superior performance compared to eight other leading commercial liquid biopsy assays in China.
February 2024
Both PredicineCARE™ and PredicineHEME™ were used to identify baseline and resistance genetic alterations to the BTK inhibitors in patients in the phase 3 ASPEN study (NCT03053440) for Waldenström Macroglobulinemia (WM). The study identified that WM patients with CXCR4MUT or TP53MUT had worse prognosis compared to patients with WT alleles and zanubrutinib led to better clinical outcomes.
February 2024
The ctDNA variant allele frequency (VAF) detected by the PredicineCARE™ liquid biopsy next-generation sequencing assay, is highly correlated with clinical outcome and play a prognostic factor for patients with advanced breast cancer.
January 2024
This study validates the clinical utility of PredicineBEACON™, a personalized minimal residual disease (MRD) liquid biopsy assay, in reinforcing Genentech’s Phase 1b clinical trial of Divarasib plus Cetuximab in colorectal cancer (CRC). In this study, PredicineBEACON™ showcased remarkable biomarker results and played an important role in evaluating treatment efficacy and identifying drug resistance mechanisms at the MRD level.
December 2023
This study included patients with ABC diagnosed at Peking University Cancer Hospital who performed ctDNA test before receiving first-line treatment. PredicineCARE™ was used to collect baseline plasma samples for assessing ctDNA alterations and VAF.
October 2023
PredicineCARE™ generated exciting data and demonstrated novel use of circulating tumor DNA (ctDNA) to identify high risk, localized upper tract urothelial carcinoma (UTUC). This research underscores the immense potential of PredicineCARE™ ctDNA platform, demonstrating ctDNA as a highly predictable and strong prognostic biomarker for selecting patients for neoadjuvant chemotherapy.
October 2023
This Genentech sponsored study demonstrated the clinical utility of blood-informed PredicineBEACON™ MRD ctDNA and PredicineWES+™ assays for target engagement, therapy monitoring, and resistance mechanism study in NSCLC, colorectal cancer, and other cancers.
August 2023
In this new research study, PredicineBEACON™ was used to demonstrate the potential for tissue-agnostic tumor-informed, urine-based MRD assay to inform clinical decision-making around organ-preserving opportunities and may fundamentally transform healthcare guidelines for MIBC patients.
August 2023
In this new research study, PredicineATLAS™ was used to assess the predictive utility of longitudinal circulating tumor DNA (ctDNA) analysis from a single-institution biomarker cohort.
August 2023
In this new research study, PredicineATLAS™ was used to assess the ability of cell-free urinary and plasma tumor DNA (cfDNA) to predict pathologic stage at radical cystectomy for patients with clinical muscle-invasive bladder cancer.
August 2023
In this new research study, machine learning models were established that provide significant prognostic prediction of metastatic prostate cancer (mPC) clinical outcomes from blood-based multi-omic data. Plasma ctDNA alterations in combination with plasma lipid species measurements were used to identify a molecular classifier in different states of mPC progression.
August 2023
In this new research study, PredicineCARE™ was used to for targeted sequencing on 407 plasma samples from 375 men with mCRPC.
August 2023
In this new research study, PredicineCARE™ was used to perform comprehensive genomic profiling on DNA extracted from formalin-fixed, paraffin-embedded samples.
June 2023
In this new research study, PredicineCARE™ was used to analyze plasma samples to assess somatic circulating tumor DNA (ctDNA) alterations.
June 2023
In this new research study, PredicineWES™ boosted whole exome sequencing was used to analyze circulating tumor DNA (ctDNA) to identify genomic features for predicting and monitoring treatment resistance.
January 2023
In this new research study, PredicineATLAS™ liquid biopsy next-generation sequencing assay was used to compare gemcitabine and nab-paclitaxel with and without immune checkpoint inhibitors durvalumab and tremelimumab in 180 patients with mPDAC. The primary endpoint was overall survival. Secondary endpoints included progression-free survival and objective response rate.
August 2022
In this new research study, PredicineCARE™ liquid biopsy next-generation sequencing assay assessed the correlations between circulating tumour DNA (ctDNA)-derived genomic markers and treatment response and survival outcome in Chinese patients with advanced breast cancer (ABC).
May 2022
In this new research study, PredicineATLAS™ (Assay B) liquid biopsy next-generation sequencing assay demonstrated superior performance compared to four other leading commercial liquid biopsy assays.
May 2022
In this study, the PredicineATLAS™ panel was used to detect germline variants in Chinese patients with advanced breast cancer.
April 2022
In this study, Predicine aimed to evaluate gemcitabine and cisplatin plus durvalub with or without tremelimumab as first-line treatment in patients with advanced biliary tract cancer.
March 2022
This study evaluates circulating tumor DNA (ctDNA) in blood or urine, which can be used as biomarkers of PCa and the combination of these markers may increase the sensitivity and specificity of the detection of PCa.
March 2022
In this study, Predicine performed a retrospective analysis of seriallyprofled cell-free DNA (cfDNA) alterations in blood samples collected from mCRPC patients before and after starting chemotherapy who were followed for response and clinical outcomes.
March 2022
In this study, Predicine assessed the association between the poor prognostic 3-lipid signature (3LS), somatic genetic aberrations and clinical outcomes in mCRPC.
March 2022
Predicine’s cfDNA and cfRNA assays were utilized to assess the role of somatic alterations on treatment resistance in patients with metastatic castration-resistant prostate cancer.
October 2021
Utilizing the PredicineCARE™ assay, this study demonstrates that urinary tumor DNA (utDNA) outperformed circulating tumor DNA (ctDNA) from blood samples in identifying somatic alterations in patients with newly diagnosed urothelial bladder cancer.
September 2021
PredicineCARE™ liquid biopsy assay was utilized to evaluate the correlation between genomic alterations and progression-free survival in patients with hormone-receptor positive metastatic breast cancer in the US and China.
September 2021
In a study of patients with mCRPC, the PredicineCARE™ and PredicineRNA liquid biopsy assays were utilized to identify alterations that may be associated with a poorer prognosis. The study also demonstrated that serial testing of cfDNA offers the unique opportunity to predict benefit to therapy prior to the onset of biochemical or radiographic changes.
September 2021
The PredicineCARE™ liquid biopsy assay was utilized to identify PTEN, RB1 and TP53 copy number losses in plasma samples from patients with metastatic prostate cancer. These findings have profound clinical implications for a patient’s prognosis, treatment selection, and understanding subsequent resistance.
August 2021
了解更多信息Using PredicineATLAS™ to analyze somatic mutations and copy number changes in PI3K/AKT pathway, NOTCH signaling pathway, hedgehog signaling pathway and pathways involved in DNA damage repair might be potential mechanisms underlying TKI resistance.
May 2021
了解更多信息Using PredicineCARE™ to analyze TP53 mutations in cell-free DNA from patients with metastatic breast cancer to investigate disease characteristics and the prognostic role of different locations of the TP53 mutation site.
April 2021
了解更多信息PTEN-PI3K-AKT pathway CNVs were detected using Predicine’s cfDNA liquid biopsy assay, with the prevalence of PTEN loss comparable with tissue-based studies. Plasma cfDNA profiling may facilitate and optimize patient selection for targeted treatment with Akt inhibitors in mCRPC.
April 2021
了解更多信息Using PredicineCARE™ to analyze mutational landscape of 158 tumor related genes in HER2-positive breast cancer patients.
November 2020
了解更多信息Using PredicineCARE™ to detect CXCR4 mutations in bone marrow samples of Waldenström macroglobulinemia patients for patient stratification.
November 2020
了解更多信息The first prospective observational clinical study that simultaneously investigates cfDNA and cfRNA focusing on AR biomarkers in two independent mCRPC cohorts.
May 2020
了解更多信息An editorial to introduce an upcoming study that leverages Predicine’s next-gen liquid biopsy technology to investigate plasma cfDNA- and cfRNA-based AR molecular profiling in metastatic castration-resistant prostate cancer.
May 2020
了解更多信息Using Predicine’s cfDNA assay to analyze the molecular evolution over the mutational landscape from mSHPC to mCRPC. Gene deletion and amplification of BRCA, PTEN, RB, AR are reported.
April 2020
了解更多信息Using Predicine’s cfDNA assay to analyze the relationship between BRCA gene status and the efficacy of platinum- and non-platinum-based regimens as first-line treatment for advanced TNBC.
February 2020
了解更多信息Validation of Predicine’s ctDNA assay reporting high concordance of variant detection in orthogonal samples between Predicine and Guardant Health’s ctDNA platforms.
January 2020
了解更多信息The potential of combining CTCs and ctDNA for comprehensive liquid biopsy analysis to accurately represent genomic heterogeneity with implications for clinical management of patients with MBC.
December 2019
了解更多信息May 2024
October 2023
October 2023
October 2023
October 2023
June 2023
June 2023
April 2023
April 2023
April 2023
April 2023
April 2023
April 2023
April 2023
April 2023
April 2023
April 2023
April 2023
April 2023
February 2023
February 2023
February 2023
February 2023
November 2022
November 2022
September 2022
September 2022
September 2022
May 2022
February 2022
February 2022
February 2022
February 2022
February 2022
December 2021
December 2019
Pan Du, Eric Jia and Zhixin Zhao
December 2019
Lorenzo Gerratana, Qiang Zhang, Ami N Shah, Alessandra Franzoni, Jianjun Yu, Shidong Jia, Andrew A Davis, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradishar and Massimo Cristofanilli
December 2019
Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Calvin Wong, Meng-Yao Tan, Shidong Jia, Jianjun Yu; H. Lee
June 2019
了解更多信息Heidi Fettke, Edmond M. Kwan, Jianjun Yu, Amy Wang, Carlos Montesinos, Calvin Wong, Xue Gong, Tiantian Zheng, Peter Pan Du, Shidong Jia, Andrew Mant, Phillip Parente, Carmel Pezaro, Arun A. Azad
April 2019
了解更多信息Zhixin Zhao, Amy Chang, Tak Cheung, Feng Xie, Carlos Montesinos, Amy Xiaohong Wang, Kemin Zhou, Shidong Jia, JIanjun Yu, Pan Du
April 2019
了解更多信息Manish Kohli, Siddhartha Yadav, Winston Tan, Irbaz Bin Riaz, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calvin Wong, Peter Du, Shidong Jia, Jianjun Yu
February 2019
了解更多信息竭诚欢迎您前来洽谈业务合作！
请留下您的联系方式，我们会尽快与您沟通交流。